Replies to post #5013052 on BB's Stock Haven

[stock1ace1]

DWTX $4.93 pending phase 2 data 1 million float $7 cash per share on balance sheet

Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track for Q4 2025

Cash on hand of $13.4 million provides operational runway through Q1 2026 -

ATLANTA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX)
https://finviz.com/news/139096/dogwood-therapeutics-reports-second-quarter-2025-financial-results